Rafivirumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | rabies virus glycoprotein |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6462H9954N1718O2036S46 |
| Molar mass | 145761.46 g·mol−1 |
  (what is this?) (verify) | |
Rafivirumab (CR57) is a monoclonal antibody for the prophylaxis of rabies.[1][2][3]
References
[edit]- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). World Health Organization.
- ^ Kramer RA, Marissen WE, Goudsmit J, Visser TJ, Clijsters-Van der Horst M, Bakker AQ, et al. (July 2005). "The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries". European Journal of Immunology. 35 (7): 2131–45. doi:10.1002/eji.200526134. PMID 15971273.
- ^ Franka R, Carson WC, Ellison JA, Taylor ST, Smith TG, Kuzmina NA, et al. (September 2017). "In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants". Tropical Medicine and Infectious Disease. 2 (3): 48. doi:10.3390/tropicalmed2030048. PMC 6082099. PMID 30270905.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |